Sign up
AHCO

Adapthealth Corp (NASDAQ: AHCO)

Healthcare · Medical Devices

$7.37−0.16 (−2.12%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. AHCO fell 2.12% in the Nov 18 session to $7.37. The borrow fee is 0.27%. Seven active firms cover the stock as of Nov 19, 2026; seven active firms with targets average $11.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuationLower multiples than peers

P/S 0.3× vs peer median 2.7×

MomentumOverbought

RSI (14) 76.4 (overbought above 70, oversold below 30)

Trend—

—

Short interest12.7% of float

FINRA settlement Oct 30, 2026

AHCO price chart

Price $7.37 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$7.41Nov 18, 2026 session
Previous close
$7.53Nov 17, 2026 close
Day range
$7.28 – $7.53Nov 18, 2026 session
52-week range—
Volume
1.54MNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

AHCO · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18
Squeeze36Watch—
How the scores work →

How AHCO compares with its industry

Against 139 other US-listed Medical Devices stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. One-month return was 28.1%, higher than 93% of 135 peers.Peer median −8.2% · As of Nov 16, 2026
  2. Five-year annualized sales growth was 25.2%, higher than 76% of 85 peers.Peer median 15.9% · As of Nov 17, 2026

Points of caution

  1. Trailing-year gross margin was 18.2%, with only 9% of 126 peers reporting a lower value.Peer median 59.0% · As of Nov 17, 2026
  2. Current ratio was 1.13, with only 12% of 130 peers reporting a lower value.Peer median 2.97 · As of Nov 17, 2026

Valuation

Lower multiples than peers

  • Price/sales0.30×2.68×
    Lowest 10%

    Higher than 10% of 133 peers

  • Forward P/E7.78×21.37×

    Not ranked: only 71 of 139 peers report it

  • Price/book0.85×2.53×

    Higher than 19% of 136 peers

Profitability

Profitability metrics are mixed versus peers.

  • Gross margin18.2%59.0%
    Bottom 10% of peers

    Higher than 9% of 126 peers

  • Operating margin3.8%−4.3%

    Higher than 69% of 124 peers

  • Net margin−11.8%−3.2%

    Higher than 41% of 137 peers

  • Return on equity−28.4%−30.2%

    Higher than 51% of 133 peers

Growth

Growth metrics are higher than most peers.

  • Quarterly sales growth, year over year10.9%9.2%

    Higher than 55% of 139 peers

  • 5-year sales growth rate25.2%15.9%

    Higher than 76% of 85 peers

Balance sheet

Balance sheet metrics are lower than most peers.

  • Current ratio1.132.97

    Higher than 12% of 130 peers

  • Debt/equity (total borrowings)1.540.53

    Not ranked: only 67 of 139 peers report it

Momentum

Returns are mixed versus peers.

  • 1-year return−18.1%−17.6%

    Higher than 50% of 123 peers

  • 6-month return−27.2%−5.8%

    Higher than 35% of 127 peers

  • 3-month return+33.0%−17.0%
    Top 10% of peers

    Higher than 92% of 133 peers

Compared with 139 other US-listed Medical Devices stocks · fundamentals as of Nov 18, 2026 · prices as of Nov 13, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

0Strong Buy
7Buy
0Neutral
0Sell
0Strong Sell

Based on 7 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$8.00
Average$11.00
High$16.00

As of Nov 19, 2026 across 7 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.06−$1.13—
Q2 2026—−$0.99—
Q1 2026$0.01−$0.12—
Annual 2025—−$0.52—
Q3 2025—$0.16—
Q2 2025—$0.10—
Q1 2025—−$0.05—
Annual 2024$0.28$0.61—

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider buyWOLF DALE BBuy$126KForm 4
Insider buySAMET KENNETH ABuy$149.9KForm 4
Insider buyWOLF DALE BBuy$117.2KForm 4
Insider buyWOLF DALE BBuy$127.4KForm 4
Insider sellSchuster III Russell E.Sell$117.7KForm 4
Insider sellSchuster III Russell E.Sell$113.4KForm 4
13FCITADEL ADVISORS LLCIncreased position$1.5M13F filing
13FMILLENNIUM MANAGEMENT LLCIncreased position$7.9M13F filing
13FTWO SIGMA INVESTMENTS, LPOpened position$223.8K13F filing
13FAQR CAPITAL MANAGEMENT LLCIncreased position$11.5M13F filing
All smart-money activity →

News and press releases

All AHCO news →

Company profile

AdaptHealth Corp., together with its subsidiaries, distributes home medical equipment (HME), medical supplies, and home and related services in the United States. It operates through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home segments. The company offers sleep therapy equipment, supplies, and related services, such as continuous positive airway pressure and BiLevel services to individuals suffering from obstructive sleep apnea; oxygen and home mechanical ventilation

CEO
Ms. Suzanne M. Foster M.P.H.
Headquarters
Conshohocken, PA, United States
Employees
10,900
IPO date
May 24, 2018
Sector
Healthcare
Industry
Medical Devices

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.